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c-Raf is a ubiquitously expressed 74 kDa serine/threonine protein
kinase which is central to the ERK pathway (Daum et al, 1994)
and has long been implicated in oncogenesis (Rapp et al, 1988;
Storm et al, 1990). Despite this, little information on c-Raf protein
expression in ovarian cancer is available. c-Raf is activated by
phosphorylation after translocation to the plasma membrane by a
mechanism that involves Ras (Avruch et al, 1994). Mutations in
ras genes have been frequently detected in ovarian tumours and
Ras protein is downstream of receptors such as the EGF/erbB
receptor tyrosine kinases (Rozakis-Adcock et al, 1993; Teneriello
et al, 1993). Compared to normal ovary and benign ovarian
tumours, malignant ovarian tumours have increased expression of
EGF receptor (erbB-1) (Stewart et al, 1992) and erbB2 (Meden
and Kuhn, 1997). The erbB receptors and Ras are currently being
investigated as potential targets for growth inhibitors in cancer
(Cowsert, 1997; Fan and Mendelsohn, 1998; Witters et al, 1999).
Targeting growth inhibitors to c-Raf in cancer cells would elimi-
nate c-Raf-mediated cell proliferation signals from these upstream
effectors and prevent cell proliferation arising from over-
expression of c-Raf. 
Targeting genes using antisense technology provides a highly
selective, sequence-specific mechanism for inhibiting the expres-
sion of a chosen gene product. A number of antisense oli-
godeoxynucleotides (ODNs) are currently undergoing clinical
trials for the treatment of cancer (Cho-Chung, 1999; Nemunaitis
et al, 1999; Yuen et al, 1999). ISIS 5132, a 20-mer phosphoroth-
ioate antisense ODN (first generation compound) that targets the
3′ untranslated region of c-Raf mRNA, inhibits the expression of
c-Raf mRNA and protein in lung, colon, cervical and prostate
cancer cells (Monia et al, 1996a; Lau et al, 1998). Second genera-
tion antisense ODNs containing 2′ -methoxyethyl sugar modifica-
tions, such as ISIS 13650, have also been developed and these may
be more potent inhibitors of mRNA expression (Monia, 1997). 
To investigate the role and function of c-Raf in ovarian cancer,
we have measured c-Raf expression in primary tumours and
ovarian cancer cell lines and studied relationships between protein
expression and histology, grade of differentiation, tumour stage
and patient survival time. To explore the therapeutic potential of
first- and second-generation c-Raf antisense ODNs in ovarian
cancer, the extent of growth inhibition following antisense ODN
treatment was investigated in ovarian cancer cell lines and a
xenograft model. Our findings demonstrate that high levels of 
c-Raf expression are important in ovarian cancer and use of anti-
sense ODNs targeted to c-Raf may provide a novel strategy for the
treatment of this disease. 
MATERIALS AND METHODS 
Tumour samples 
Fresh primary ovarian tumour tissue was obtained from 53 previ-
ously untreated patients with epithelial ovarian cancer at initial
debulking surgery, transferred to liquid nitrogen, then formalin-
fixed and embedded in paraffin. Tumour histology was assessed
on paraffin embedded sections and classified according to WHO
criteria (details in Table 1). 
Cell lines 
PEO1, PEO1CDDP, PEO4, PEO6, PEO14 and PEO16 were estab-
lished as described previously (Langdon et al, 1988); SKOV-3 and
CaOV3 cells were obtained from the American Type Culture
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OVCAR5 were obtained from Dr TC Hamilton (Fox Chase
Institute, Philadelphia, PA, USA); 41M, 59M, OAW42 and A2780
cells were obtained from the European Tissue Collection (Porton
Down). All cell lines were routinely grown as monolayer cultures
in RPMI 1640 (Life Technologies Inc, Gaithersburg, MD) supple-
mented with 10% heat-inactivated fetal calf serum and 100 iu ml–1
penicillin/streptomycin. Cells were maintained at 37˚C in a 5%
CO2 humidified incubator. 
Immunohistochemistry 
Sections (3 µ m) were deparaffinised and rehydrated. Endogenous
peroxidase activity was blocked by incubating sections in 3%
H2O2 for 30 min immersing in citric acid buffer (0.005M, pH 6.0)
and microwaving for 3 × 5 min. Slides were washed in 0.05M
Tris/HCI buffer (pH 7.6) then incubated in 20% fetal calf serum in
the above Tris buffer for 10 min. Anti-c-Raf antibody (R19120,
Transduction Laboratories) was used at 1:10–1:20 dilution in 20%
fetal calf serum and sections were incubated for 1.5–2 h. A 
streptavidin–biotin multilink method (StrAviGen Multilink kit;
Biogenex, San Ramon, CA) was used to detect reactivity. Sections
were stained with a secondary multilink antibody at a 1:20 dilution
for 30 min, then incubated with a horseradish-peroxidase-labelled
streptavidin complex at a 1:20 dilution for 30 min. 
Diaminobenzidine tetrachloride was used as chromagen and
applied for 5 min. Sections were lightly counterstained in haema-
toxylin, dehydrated and mounted. Negative controls for each
tumour section were included by replacing the primary antibody
with Tris buffer. Immunoreactive scores between 0 and 12 were
generated for each sample and represent the product of intensity (0 =
negative, 1 = weak, 2 = moderate, 3 = strong) and percentage posi-
tive cell staining (0 = 0%, 1 = 1–25%, 2 = 26–50%, 3 = 51–75%,
4 = 76–100%). 
Statistics 
Relationships between variables were analysed using the Fisher’s
exact test, the student t-test and the Mann–Whitney test where
appropriate. Differences in survival were determined using the
Kaplan–Meier method and groups were compared using the log-
rank test and χ 2 test. 
Western blotting 
Cells were grown to 70% confluence, washed twice with PBS, and
lysed in ice cold hypotonic lysis buffer (50 mM Tris-HCI (pH 7.5),
5 mM EGTA (pH 8.5), 150 mM NaCl, 1% Triton X-100, 2 mM
sodium orthovanadate, 50 mM sodium fluoride, 1 mM phenyl-
methanesulfonylfluoride, 10 µ g ml–1 leupeptin, 10 µ g ml–1 apro-
tinin and 10 mM sodium molybdate). Lysates were centrifuged for
6 min at 13 000 rpm in a microfuge. Tumour samples (100 mg)
were finely chopped, then homogenized on ice in a Silverson
homogenizer in 1.8 ml lysis buffer (excluding Triton X-100).
Samples were incubated on ice after the addition of 1% Triton X-
100, then centrifuged 14 000 rpm for 30 min. Protein concentra-
tions of supernatants were determined using the Bio-rad Protein
Assay Kit (Bio-rad, Richmond, CA). Cell lysates (30 µ g) or
tumour lysates (50 µ g) were resolved on 10% or 12% SDS-PAGE
then transferred electrophoretically overnight onto Immobilon-P
membranes (Millipore, Bedford, MA). After transfer, membranes
were blocked with 1% blocking agent in TBS (20 mM Tris-HCl,
137 mM NaCI, pH 7.5) before probing with the appropriate
primary antibody, anti-c-Raf (R19120, Transduction Laboratories,
Lexington, KY), anti-A-Raf (R14320, Transduction Laboratories),
anti-ERK (E16220, Transduction Laboratories) overnight at 4˚C.
Immunoreactive bands were detected using enhanced chemilumi-
nescent reagents (1520709, Boehringer Mannheim) and Hyperfilm
ECL (Amersham, Buckinghamshire, UK). 
Antisense ODNs 
Antisense ODNs targeted to the 3′ untranslated region of c-Raf
mRNA (sequence: TCCCGCCTGTGACATGCATT) were supplied
by ISIS Pharmaceuticals (Carlsbad, CA). Two forms of the anti-
sense ODNs were used: a first generation compound (ISIS 5132)
which has a phosphorothioate backbone and a second generation
compound (ISIS 13650) which also has a phosphorothioate back-
bone and the addition of 2′ methoxyethyl groups on the sugar
moiety. 2 control ODNs were available: a second generation random
ODN (ISIS 16971; sequence, TCACATTGGCGCTTAGCCGT)
and a first generation mismatch ODN (ISIS 10353 sequence,
TCCCGCGCACTTGATGCATT). 
Growth and protein inhibition experiments 
For growth inhibition experiments, log phase cells were
trypsinized and seeded into 24-well tissue culture plates (1 × 104 in
1 ml) and incubated to reach 40–60% confluence. Cells were then
washed with PBS before adding 250 µ l of Optimem (Gibco-BRL)
containing ‘Lipofectin’ (Gibco-BRL) (6 µ lm l –1). Antisense and
random ODNs were added (50 nM–200 nM) from 50 µ M stock
solutions. Cells were incubated at 37˚C for 3 h, washed with PBS,
replenished with RPMI (plus 10% fetal calf serum and 100 iu ml–1
penicillin/streptomycin) and replaced in the incubator for the
remainder of the time course. Cells were trypsinized and counted
at the appropriate time point using a ‘ZM’ Coulter Counter. 
c-Raf protein inhibition experiments were carried out as above
except that cells (2.5 × 105 in 4 ml) were plated into 60 mm diam-
eter petri dishes and washed with PBS (2 ml) prior to addition of
Optimem/Lipofectin/ODN (1 ml). Cells were lysed and analysed
by Western blotting as previously described. 
Cell cycle analysis 
DNA analysis of treated cells was carried out on a Becton
Dickinson  ‘FACSCalibur’ flow cytometer using methodology
described by Levack et al (1987). 
Apoptosis assay 
SKOV-3 cells were treated with ODNs as described above and
apoptosis was measured using the TACS Annexin V-FITC kit 
(R& D Systems) following the prescribed protocol. 
Xenograft experiments 
Female adult nude (nu/nu) mice were obtained from ICRF
(Clare Hall, South Mimms, UK) and maintained in negative pres-
sure isolators. SKOV-3 cells (5 × 106 cells/injection) were injected
into both flanks of 2 groups of mice. The control group
consisted of 10 mice (2 tumours/mouse) and the treatment groups
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the days indicated. Tumour volumes, assessed twice weekly by
caliper measurements of the tumour in 2 dimensions, were calcu-
lated by the formula π /6 × length × width2. Treatment was initiated
either 24 h after cell implantation or when tumours had reached a
median diameter of 4 mm. Relative tumour volume was evaluated
by dividing the volume at day × (the number of days after the start
of treatment) by the volume at day 0 (the day treatment started).
UKCCCR Guidelines (1998) were followed throughout. 
RESULTS 
c-Raf expression in primary ovarian cancer 
c-Raf expression was identified in 49 of 53 ovarian cancer sections
and varied from weak to intense staining (examples are illustrated
in Figure 1A). Immunoreactivity was found almost exclusively in
the epithelial cells with only minor staining in the stroma. The
relationships between immunoreactive scores and clinical and
pathological parameters are represented in Table 1. Serous adeno-
carcinomas expressed higher levels of c-Raf than all other
subtypes combined (P = 0.005, Fisher’s exact test). No significant
associations between c-Raf expression level and either stage (I / II
vs III / IV, P = 0.18 Fisher’s exact test) or grade of differentiation
(poor vs moderate/well, P = 0.17, Fisher’s exact test) were
observed. 
Survival data were available for 52/53 patients. High c-Raf expres-
sion was linked with poor survival in this group (Figure 1B). The
survival of patients whose tumours had an immunoreactive score ≥ 7
(n = 14) was significantly poorer than that of patients with scores ≤ 6
(n = 38) (P = 0.002, log-rank test). Since histology and stage are
major prognostic variables, we also analysed survival in patients
having stage III serous adenocarcinomas which represented a
majority sub-group (n = 28). Again patients whose tumours had a
higher level of c-Raf expression (immunoreactive score of ≥ 7) (n =
12) had significantly poorer survival (P = 0.035, log-rank test) than
patients with tumours expressing lower levels of c-Raf (n = 16). 
c-Raf expression in ovarian cancer cell lines 
c-Raf protein, detected by Western blotting, was evident in all 15
cell lines analysed. Levels of c-Raf varied 24-fold between cell
lines, compared to only a 2.5-fold and 11-fold variation in ERK
and A-Raf respectively (Figure 2A and 2B). 
Antisense oligonucleotides reduce c-Raf protein levels
in SKOV-3 cells 
The ability of the antisense ODNs ISIS 13650 and ISIS 5132 to
selectively reduce the amount of c-Raf protein was investigated in
c-Raf in ovarian cancer 1755
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Table 1 c-Raf expression in primary ovarian cancer 
Number of patients with 
immunoscorea Immunoscore
0–6 7–12 P value 
All tumours 39 14 
Stage 
I / II 13 2 0.18b
III / IV 23 12 
Differentiation 
Well / moderate 14 2 0.17b
Poor 21 11 
Histology 
Serous 16 12 
Endometrioid 17 1 0.005c
Clear cell 5 1 
Mucinous 1 0 
The expression of c-Raf was determined by immunohistochemical staining as
described in Materials and Methods and scores between 0 and 12 were
generated for each sample. a53 patient samples were analysed for
expression but information on stage and grade were available for 50 and
48 patients respectively. bFisher’s exact test. cFisher’s exact test (serous vs
rest). 
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Figure 1 High c-Raf expression is associated with poor survival in ovarian
cancer. (A) Examples of c-Raf immunoreactivity, detected as described in
‘Materials and Methods’. Epithelial cells are diaminobenzidine positive
(brown) and counterstain is hematoxylin (blue). Low and high power
magnifications. (B) Kaplan–Meier survival curves with log-rank analysis; high
expressers vs low expressers (P = 0.002) 
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Figure 2 (A) Expression of c-Raf, A-Raf and ERK2 in 15 ovarian cancer
cell lines. Cells were lysed and samples electrophoresed as described in
‘Materials and Methods’. Blots were probed with anti-c-Raf, anti-A-Raf or
anti-ERK2. Data shown is a typical result of n = 3. (B) Densitometric analysis
(Integrated Optical Density units) of c-Raf expression, n = 3 SKOV-3 cells. After 48 h, both ODNs reduced c-Raf levels at
100 nM and 200 nM (Figure 3A). In comparison, similar concen-
trations of the random control ODN ISIS 16971 had no effect on
c-Raf levels. The specificity of ISIS 5132 for c-Raf was examined
by measuring its effects on A-Raf and ERK and after 48 h, ISIS
5132 (200 nM) had no effect on the expression of either of these
proteins (Figure 3B). To determine the time required for c-Raf
antisense ODNs to exert their effects on c-Raf protein, the level of
c-Raf present in SKOV-3 cells was assayed at various intervals
following antisense treatment. Both ISIS 13650 (200 nM) and
ISIS 5132 (200 nM) reduced c-Raf levels by > 50% at 24 h and
almost complete removal of c-Raf protein was observed at 48 h
(Figure 3C). 
c-Raf antisense ODNs inhibit cellular proliferation in
SKOV-3 cells 
To evaluate the effectiveness of c-Raf antisense ODNs as anti-
proliferative agents, SKOV-3 cells were treated with ISIS 13650,
ISIS 5132 or random ODN and the cell number determined 72 h
after treatment. At 200 nM both ISIS 13650 and ISIS 5132 
demonstrated > 80% inhibition of cell growth, compared to <30%
inhibition shown by the random ODN (Figure 4A). The time
required for c-Raf antisense ODNs to exert their effects on cell
proliferation was investigated in SKOV-3 cells. Cells not exposed
to ODN (control cells) and cells treated with mismatch ODN (200
nM) grew steadily over the time course demonstrating a 3-fold
increase in cell number over the 72 h period (Figure 4B). In
contrast, the addition of 200 nM ISIS 5132 or ISIS 13650 resulted
in marked growth inhibition at all time points investigated, with
both antisense ODNs preventing cell growth in the first 24 h after
treatment (Figure 4B). 
Effect of c-Raf antisense ODNs in a panel of ovarian
cancer cell lines 
The ability of c-Raf antisense ODNs to inhibit cell growth was
further investigated in a panel of 12 ovarian cancer cell lines 48 h
after treatment. Both ISIS 13650 and ISIS 5132 inhibited cell
proliferation by ≥ 60% in 9/12 cell lines examined (Figure 4C)
compared to < 30% inhibition shown by the random ODN in
selected cell lines. 
ISIS 5132 causes cell cycle arrest and enhanced
apoptosis in SKOV-3 cells 
DNA analysis showed an accumulation of cells arrested in the S
and G2/M phases of the cell cycle with a concomitant reduction in
the G0/G1 phase. These specific effects were dose-dependent and
not seen in either untreated cells or cells treated with ISIS 16971
(Figure 5A). A dose-dependent enhancement of apoptosis was
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Figure 3 Effect of c-Raf antisense ODNs on c-Raf protein level in SKOV-3
cells. After treatment with ISIS 5132, ISIS 13650 or ISIS 16971, cells were
lysed and samples electrophoresed and probed with anti-c-Raf, anti-A-Raf or
anti-ERK antibodies as described in ‘Materials and Methods’. (A) Suppression
of c-Raf protein by c-Raf antisense oligonucleotides but not a random ODN.
(B) Suppression of c-Raf but not A-Raf and ERK by ISIS 5132 at 48 h after
treatment. (C) Effect of time of c-Raf protein reduction by ISIS 5132 and ISIS
13650 
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Figure 4 C-Raf antisense ODNs inhibit growth in ovarian cancer cell lines.
(A) 72 h after treatment with ISIS 5132, ISIS 13650 or ISIS 16971 SKOV-3
cells were trypsinized and counted on a ‘ZM’ Coulter Counter. Cell counts
taken at day 0 (the day treatment began) are deducted from the 72 h cell
count. The value at each concentration is expressed as the percentage
growth compared to 100%, the value obtained from untreated cells grown for
72 h. (B) SKOV-3 cells were counted at 24, 48 and 72 h after treatment with
ISIS 5132, ISIS 13650 or ISIS 16971. (C) 72 h after treatment with ISIS 5132
or ISIS 13650 cells were trypsinized and counted. In all cell lines except
OVCAR5 growth rates of treated cells are significantly different from
untreated cells (P < 0.05; student t-test) similarly seen in cells treated with ISIS 5132 compared with
untreated cells or cells exposed to ISIS 16971 (Figure 5B). 
ISIS 5132 inhibits growth of SKOV-3 ovarian cancer
xenografts 
ISIS 5132 inhibited the growth of SKOV-3 cells implanted as a
subcutaneous xenograft in the flanks of nude mice. Treatment
initiated 24 h after implantation of cells reduced the growth rate of
these tumours at both 10 and 25 mg kg–1 day–1 compared to a
vehicle control (Figure 6A). A mismatch control (ISIS 10353) was
available for these studies and had no effect on growth. When
treatment was delayed until tumours had reached a median size of
4 mm, ISIS 5132 (25 mg kg–1 day–1) again produced a significant
effect on growth (Figure 6B). 
DISCUSSION 
In the present study, which is the first to look at the prognostic
significance of c-Raf expression in ovarian cancer, we show that
high c-Raf expression is a negative prognostic factor. c-Raf was
present in 92% of the ovarian adenocarcinomas investigated and a
high level of c-Raf expression correlated significantly with both
poor survival and serous histology. Within the serous subset, there
was again a significant correlation between expression and
survival, indicating that high c-Raf expression is associated with
poor survival irrespective of other parameters such as histology
and stage. The epithelial tumour cells were highly positive for c-
Raf staining compared to stromal cells, which showed little c-Raf
expression. 
The c-Raf signalling pathway plays an important role in the
growth regulation of some ovarian cancers. ERK activation has
previously been identified in ovarian cancer cell lines and attributed
to an increase in MEK and c-Raf activity (Hoshino et al, 1999). In
addition, ERK activation has been shown to correlate linearly with
increasing concentrations of MEK (Zheng and Guan, 1993). These
data in combination with our finding that c-Raf is highly expressed
in most of the ovarian cancer cell lines suggest that an increase in 
c-Raf level may contribute to increased signalling through the ERK
pathway. Further analysis of the ERK signalling pathway in ovarian
cancer cell lines is essential to elucidate the role of c-Raf in this
disease, and will form the basis of future studies. 
The use of antisense ODNs has allowed us to establish that c-Raf
plays an important role in the proliferation of ovarian cancer cell
lines, supporting conclusions of other studies that c-Raf is a critical
mediator of oncogenic transformation (Storm et al, 1990; Daum
et al, 1994). We have shown that both ISIS 5132 and ISIS 13650
reduce c-Raf protein in SKOV-3 ovarian cancer cells, in line with
observations in other disease types (Monia et al, 1996a; Monia,
1997; Lau et al, 1998). Evidence to support specificity was provided
by the observations that while c-Raf was reduced, related signalling
molecules were unaffected and a random ODN (ISIS 16971) had no
effect on c-Raf protein expression. 
Investigation of the effects of antisense ODNs in a panel of
ovarian cancer cell lines has allowed an insight into the efficiency
of these antisense compounds in a range of cell types with variable
amounts of c-Raf protein. Despite a 24-fold variation in c-Raf
c-Raf in ovarian cancer 1757
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Figure 6 Effect of ISIS 5132 on in vivo growth of SKOV-3 cells.
(A) Treatment initiated 24 h after implantation of 5 × 106 cells s.c. ISIS 5132
was administered i.p. at 25 or 10 mg kg–1 day–1 for 21 days and compared
with a mismatch control (ISIS 10353–25 mg kg–1 day–1) or vehicle only. 
(B) ISIS 5132 treatment of advanced SKOV-3 tumours. Tumours were
allowed to grow for 35 days before treatment (mean diameter = 4 mm).
Relative tumour volumes after 3 and 5 days treatment are shown. Mean ±
standard errors of at least 10 tumours indicated. *significantly different from
vehicle, P < 0.05 (t-test) protein levels between the cell lines, both ISIS 5132 and ISIS
13650 substantially reduced cell growth. Most of the cell lines
were > 60% growth inhibited, while 3 cell lines (A2780, OVCAR5
and CaOV3) were < 40% growth inhibited by antisense ODNs.
These intercellular growth inhibitory differences cannot be
accounted for by the variation in c-Raf protein levels between the
cell lines. Explanations for these differences are likely to come from
further analysis of the growth signalling pathways in these cells. It
is also possible that some cell lines do not require c-Raf for
cellular proliferation. Such observations have been reported in a
study investigating constitutive activation of the ERK signalling
pathway in over 100 different tumour cell lines, including
OVCAR3, SKOV-3 and OVCAR5 (Hoshino et al, 1999). Both
OVCAR3 and SKOV-3 demonstrated high constitutive activation
of the ERK pathway and in our study these cell lines were growth
inhibited to a great degree by c-Raf antisense ODNs. In contrast,
OVCAR5 exhibited minimal constitutive ERK activation that was
not increased upon stimulation with serum (Hoshino et al, 1999).
This suggests that OVCAR5 may not signal predominantly
through c-Raf, and may explain our inability to inhibit OVCAR5
cell proliferation with antisense ODN. Consequently, some
ovarian cancer types may be highly responsive to therapies that
target c-Raf, while others may not. 
Finally, we have demonstrated that ISIS 5132 is effective in vivo,
significantly inhibiting the growth of the SKOV-3 xenograft. ISIS
5132 is presently undergoing clinical trials and has been shown to
significantly reduce levels of c-raf mRNA in peripheral blood
mononuclear cells. This was associated with clinical benefits in
2 out of 14 patients with a mixture of advanced solid tumours
(O’Dwyer et al, 1999). ISIS 5132 has been rigorously examined and
an antisense mechanism of action has been confirmed (Monia et al,
1996b). Our data further support the validity of ISIS 5132 as an anti-
cancer drug that specifically targets c-Raf. In addition we provide
evidence that the 2nd generation c-Raf antisense oligonucleotide
(ISIS 13650) reduces c-Raf protein levels and inhibits cellular
proliferation with potency comparable to ISIS 5132 in vitro. 
In summary, our findings demonstrate an association between
high levels of c-Raf expression and reduced survival time for
patients with ovarian adenocarcinomas suggesting an important role
for c-Raf in tumour growth, although the extent of tumour types that
heavily depend on c-Raf remains to be explored. We have shown
that ODNs that specifically target c-Raf are effective growth
inhibitors for the majority of ovarian cancer cells. In addition, the
use of antisense ODNs will help identify cells that rely on c-Raf for
growth. Studies examining the effects of ISIS 5132 and ISIS 13650
in vivo and in combination with other standard chemotherapeutic
agents will give further information on the practical application of
antisense ODNs for the treatment of cancer. 
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